Secukinumab Relieves Severe Endplate Inflammation in a Patient With Chronic HBV Infection: A Case Study

0
0
0

Secukinumab Relieves Severe Endplate Inflammation in a Patient With Chronic HBV Infection: A Case Study

Low back pain (LBP) affects millions worldwide, and one common but understudied cause is endplate inflammation—painful irritation of the spinal disc’s bony edges. For years, doctors relied on symptom-focused treatments like vertebroplasty (spinal bone cement) or steroid injections, but new research suggests targeting the immune system could offer lasting relief. A 2021 case study from leading Chinese rheumatology centers highlights how secukinumab—a drug normally used for psoriatic arthritis or ankylosing spondylitis—helped a patient with endplate inflammation and chronic hepatitis B virus (HBV) infection reclaim her life.

The Patient’s Story: 5 Years of Pain, Then Hope

Consider a 36-year-old woman living with chronic HBV who struggled with severe LBP for 5 years. Her pain worsened so much she could barely bend over, get out of bed, or turn in sleep. Routine tests showed elevated inflammation (erythrocyte sedimentation rate, ESR: 37 mm/1h) but no signs of spondyloarthritis—a related spine condition. Her HLA-B27 (a genetic marker for spondyloarthritis) was negative, and an MRI of her sacroiliac joints (key in spondyloarthritis) looked normal. A lumbar spine MRI, however, revealed critical clues: poor vertebral alignment, bone destruction, and bone marrow edema—hallmarks of endplate inflammation.

Treatment With Secukinumab: Targeting the Root Cause

The team turned to secukinumab, a monoclonal antibody that blocks interleukin-17A (IL-17A)—a protein that drives inflammation in autoimmune conditions. Here’s what happened:

  • Dosing: 150 mg subcutaneously weekly for 5 weeks, then monthly.
  • 3-Month Follow-Up: Her pain eased significantly.
  • 6-Month Follow-Up: Her inflammation (ESR) dropped to normal, her pain score (visual analog scale, VAS) fell from 7 (severe) to near 0, and her disability score (Oswestry Disability Index, ODI) plummeted from 38 (severe disability) to minimal. A repeat lumbar MRI showed the bone marrow edema—an indicator of active inflammation—had vanished.

Her HBV status was closely monitored: HBV-DNA levels rose slightly from 48.4 to 113 IU/mL but stayed below the threshold for antiviral treatment. Infectious disease specialists recommended continued monitoring, not immediate therapy.

Why Secukinumab Worked: The Science of IL-17A

Endplate inflammation and spondyloarthritis both involve overactive immune cells called T helper 17 (Th17) lymphocytes, which release IL-17A. This cytokine fuels harm in two key ways:

  1. Inflammation: IL-17A attracts immune cells to the spine, worsening irritation.
  2. Bone Damage: It activates bone-forming stem cells (leading to painful bone spurs) and boosts osteoclasts—cells that break down bone.

A 2019 study found higher IL-17 levels in the intervertebral discs of endplate inflammation patients, confirming the cytokine’s role in disease. By blocking IL-17A, secukinumab calmed inflammation and stopped bone destruction—something pain-relief treatments can’t do.

What This Means for Patients and Doctors

For the 36-year-old woman, secukinumab meant reclaiming daily activities she’d lost to pain. For doctors, it’s a proof of concept: Targeting IL-17A could move endplate inflammation treatment beyond “managing pain” to “healing the spine.”

But important caveats remain:

  • Single Case: This is one patient—larger studies are needed to confirm secukinumab’s efficacy and safety for endplate inflammation.
  • HBV Monitoring: IL-17A affects liver cells, so patients with HBV or other viral infections need close follow-up. While this patient’s HBV stayed under control, long-term data is missing.

The Team Behind the Research

The study was led by rheumatology experts at two top Chinese institutions:

  • Rui-Hong Hou (Peking Union Medical College Hospital/Shanxi Bethune Hospital)
  • Xiao-Ting Wen (Shanxi Bethune Hospital)
  • Qian Wang (Peking Union Medical College Hospital)
  • Li Wang (Peking Union Medical College Hospital, corresponding author)

Patient Consent

The patient provided written consent for the publication of her case, including clinical images and data. Efforts were made to protect her identity, though full anonymity cannot be guaranteed.

References

  1. Rosine N, Miceli-Richard C. Innate cells: the alternative source of IL-17 in axial and peripheral spondyloarthritis? Front Immunol. 2020;11:553742. doi: doi.org/10.3389/fimmu.2020.553742
  2. Wang J, Sun W, Bond A, et al. A positive feedback loop between Th17 cells and dendritic cells in patients with endplate inflammation. Immunol Investig. 2019;48:39–51. doi: doi.org/10.1080/08820139.2018.1496097
  3. Schett G, Lories RJ, D’Agostino MA, et al. Enthesitis: from pathophysiology to treatment. Nat Rev Rheumatol. 2017;13:731–741. doi: doi.org/10.1038/nrrheum.2017.188
  4. Zhang XM, Liu CY, Shao ZH. Advances in the role of helper T cells in autoimmune diseases. Chin Med J. 2020;133:968–974. doi: doi.org/10.1097/CM9.0000000000000748
  5. Chen YF, Chen J, Li LJ. The role of intestinal microbiota, bile acids, and Th17/IL17 axis in hepatitis B virus-related liver fibrosis. Chin Med J. 2020;133:2902–2904. doi: doi.org/10.1097/CM9.0000000000001199

The original study was published in Chinese Medical Journal (2021;134(21):2644–2646) by the Chinese Medical Association. doi: doi.org/10.1097/CM9.0000000000001801

Was this helpful?

0 / 0